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ABSTRACT: A significant number of fractures develop non-union. Mesenchymal stem cell (MSC) therapy may be beneficial, however,
this requires cell acquisition, culture and delivery. Endogenous mobilization of stem cells offers a non-invasive alternative. The
hypothesis was administration of VEGF and the CXCR4 antagonist AMD3100 would increase the circulating pool of available MSCs
and improve fracture healing. Ex-breeder female wistar rats received VEGF followed by AMD3100, or sham PBS. Blood prepared for
culture and colonies were counted. P3 cells were analyzed by flow cytometry, bi-differentiation. The effect of mobilization on fracture
healing was evaluated with 1.5mm femoral osteotomy stabilized with an external fixator in 12–14 week old female Wistars. The
mobilized group had significantly greater number of cfus/ml compared to controls, p¼ 0.029. The isolated cells expressed 1.8% CD34,
35% CD45, 61% CD29, 78% CD90, and differentiated into osteoblasts but not into adipocytes. The fracture gap in animals treated with
VEGF and AMD3100 showed increased bone volume; 5.221.7mm3 and trabecular thickness 0.05 0.01mm compared with control
animals (4.33.1mm3, 0.04 0.01mm, respectively). Radiographic scores quantifying fracture healing (RUST) showed that the animals
in the mobilization group had a higher healing score compared to controls (9.6 vs. 7.7). Histologically, mobilization resulted in
significantly lower group variability in bone formation (p¼0.032) and greater amounts of bone and less fibrous tissue than the control
group. Clinical significance: This pre-clinical study demonstrates a beneficial effect of endogenous MSC mobilization on fracture
healing, which may have translation potential to prevent or treat clinical fractures at risk of delayed or non-union fractures.  2018
The Authors. Journal of Orthopaedic Research1 Published by Wiley Periodicals, Inc. on behalf of Orthopaedic Research Society.
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A significant number of bone defects and fractures do
not heal. In the USA, it is estimated that around
100,000 fractures per year go on to non-union.1 The
UK National Health Service reports around 10% of
fractures fail to heal, and treatment can be difficult
requiring repeat surgery with a cost of up to £80,000
per patient.2 Successful fracture healing is reliant
upon the recruitment, migration and homing of cells
for inflammation, blood vessel formation, chondrogen-
sis, osteogenesis.3 Adult mammalian bone marrow has
two constituent stem cell populations with separate
lineages, including haematopoietic stem cells which
are non-plastic adherent and will circulate in the
peripheral blood, and stromal cells, which are plastic
adherent, with a fibroblastic morphology and consid-
ered non-circulating.4 Cells isolated from stroma have
been shown in vitro and in vivo transplantation to be
able to produce all tissues require for the bone organ4,5
and are termed mesenchymal stem cells (MSCs).
There is evidence for low numbers (1 in 106–8 of
nucleated cells) of peripheral blood circulating plastic
adherent, osteogenic potent cells in mice, rabbits,
guinea pigs and humans.6,7 Clinical evidence from
fracture patients also supports a role for circulating
MSCs in fracture healing.8
The chemokine stromal cell derived factor 1 (SDF1,
also known as CXCL12), and its receptor CXCR4, has
a key role in stem cell migration from the bone
marrow stroma into the circulation and is believed to
be important for homing of stem cells to a fracture
sites.9 Local increases in SDF1 expression have been
measured in distraction osteogenesis, stress fractures
and segmental defects.9,10 It is suggested that when a
fracture occurs there is a chemotactic gradient, with
high levels of SFD1 at the fracture site, and subse-
quently increased levels in the blood steam, facilitat-
ing stem cell migration from their niches.9
The SDF1-CXCR4 axis maintains HSCs and likely
other stem cells in the bone marrow9,11 and probably
within other body niches. An intentional forced egress of
cell ‘mobilization’ has been in clinical use for some time
with haematopoietic stem cells for repopulation of the
bone marrow after treatment for certain blood related
malignancies.12,13 AMD3100, (1,1-[1,4-Phenylenebis-
(methylene)] bis-1,4,8,11-tetraazacyclotetradecane octa-
hydrochloride), is a bicyclam derivative that antagonises
the CXCR4 receptor directly and mobilizes a population
of CD34þ haematopoietic stem cells into the peripheral
circulation. This occurs by highly selective, high affinity
competitive blocking of the CXCR4 receptor which
displaces stem cells from the bone marrow niche by
disruption of their attraction to SDF1.14 Although
haematopoietic stem cells have been successfully mobi-
lized using GCSF or AMD3100 or a combination, work
on MSC and other progenitors is limited and these cells
do not seem to be as migratory as hematopoietic stem
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cells, potentially due to their larger size, increased niche
adherence and their limited number in the bone marrow
stroma.15 Pitchford’s seminal work on different mobiliza-
tion protocols in mice, demonstrated that AMD3100
combined with VEGF rather than GCSF, preferentially
mobilizes a population of MSCs rather than haemato-
poietic stem cells.11
The aim of this study was to investigate whether
administration of VEGF with AMD3100, could mobi-
lize MSCs into the peripheral circulation of rats, and
to determine whether increasing the circulating levels
of MSCs would improve fracture healing in a delayed
union rat femoral fracture model.
METHODS
Isolation of Bone Marrow MSCs (BMMSCs)
Healthy, ex-breeder female wistar rats (n¼ 3) (450–550 g),
were the donors. All procedures were carried out according
to the UK Home Office Animals Scientific Procedures Act of
1986 and were approved by the Animal Welfare Ethical
Review Board at the Royal Veterinary College, and aligned
to the ARRIVE guidelines. The rats were euthanized and the
femur aseptically isolated. The femoral medullary canal was
flushed with 5ml DMEM 4500mg/L glucose, (Sigma–Aldrich,
UK) with 20% fetal calf serum (FCS) and 1% penicillin/
streptomycin (termed “media”), into a 25 cm2 polystyrene cell
culture flask (Corning). The cells were cultured in a humidi-
fied incubator at 37˚C, 95% air and 5% CO2. The media was
changed after 5–7 days to remove non-adherent cells and
every 3–4 days thereafter. Once they had reached 70–80%
confluence, they were passaged.
Preparation of Growth Factors for Mobilization
Rat Vascular Endothelial Growth Factor 165 (VEGF) (Pepro-
Tech, 400–31) was prepared by dissolving the lyophilized
product in sterile water to make a 0.1mg/ml stock solution.
A working solution was prepared by adding 1ml of stock
solution to 4mls of sterile PBSþ 0.1%BSA (Sigma–Aldrich,
UK), to achieve a 100mg/ml injectable solution which was
then aliquoted and stored at 20˚C until needed. AMD3100
(Sigma–Aldrich A5602), stock solution was prepared by
dissolving 5mg lyophilized product in 0.5ml sterile water,
and then added to 4.5mls PBS to produce a 1mg/ml injection
solution, which was then aliquoted and stored at 20˚C,
until needed.
Mobilization of Peripheral Blood MSCs (PBMSCs)
For the mobilization study, the VEGF-AMD group (n¼ 8)
and PBS treated controls (n¼ 6) were healthy, ex-breeder
female Wistar rats (380–600 g). Rats were pre-treated with
VEGF (Peprotech), at 100mg/kg, once daily by intra-perito-
neal (i.p.) injection daily for four days, at a volume of 0.5mls/
100 g. On day five, rats received a single i.p. 5mg/kg dose of
AMD3100, at a volume of 0.5mls/100g. The dosages of VEGF
and AMD3100 were taken from Pitchford’s et al.11 based on
prior pharmacokinetic work12 and were adjusted to be
appropriate for each individual rat’s bodyweight.
One hour post administration, rats were anaesthetized for
terminal cardiac venipuncture. Controls were treated with
PBS i.p. at the same volume and time intervals (Fig. 1a).
Isolation of stem cells was achieved by red blood cell lysis
where 10ml of lysis solution (Red Blood Cell lysing Buffer
Hybri-Max solution Sigma–Aldrich, UK), was added per 1ml
of blood, and mixed in a 50ml Falcon tube (Corning). After
5min, 35ml of PBS was added to neutralize the lysis
solution, and then centrifuged at 400g for 5min. The
supernatant was aspirated and the cells were re-suspended
in media and plated into 25cm2 polystyrene cell culture
flasks for MSC culture. The media was changed after five to
seven days to remove non-adherent cells and thereafter
every 3–4 days. Colonies were counted at 4 magnification
placed under a phase-contrast light microscope, using a grid
overlay. Final CFU count was performed at 20 2 days. Cells
were passaged when they were 70–80% confluent, as previ-
ously described.
Analysis of Isolated Cells
P3 cells, 30,000 cells per group were fixed and assessed using
a combination of positive CD90 (Anti-Mouse/Rat CD90.1
(Thy-1.1) eBiosceince, UK) and CD29 (Anti-Mouse/Rat CD29
(Integrin beta 1) eBioscience, UK), and negative MSC
markers CD45 (Anti-Rat CD45 eBioscience, UK) and CD34
(Anti-CD34 abcam, UK) and were compared with appropriate
isotopye controls. Analysis was performed using a flow
cytometer (Cytoflex, Beckman Coulter, UK), with Cytexpert
(Beckman Coulter, UK) software.
For differentiation, cells isolated from blood and from
bone marrow were assessed by taking 30,000 P3 cells were
seeded into a sterile 48 well plates, in triplicate and assessed
for osteogenic and adipogenic differentiation through media
supplementation for 21 days in comparison to standard
media. Osteogenic media consisted of standard media with
100nM dexamethasone (Sigma–Aldrich), 50mg/ml L-ascorbic
acid 2-phosphate (Sigma–Aldrich) and 10mM Glycerol-2-
phosphate disodium salt hydrate, (Sigma–Aldrich). Adipo-
genic media consisted of standard media with 0.1mM
dexamethasone (Sigma–Aldrich), 0.45mM IBMX (Sigma–
Aldrich), 10mg/ml Insulin (1.7mmol/L) (Sigma–Aldrich), and
50mM Indomethacin (Sigma–Aldrich). Osteogenic differenti-
ation was assessed by staining with Alizarin red stain (0.2
Molar, pH 4.32, Sigma–Aldrich), to identify calcium mineral
deposition. Adipogenic differentiation was assessed with Oil
red O staining for lipid droplets.
Femoral Delayed Union Fracture Model
For the fracture model, 12–14 week old female Wistar rats
were assigned to the control (n¼ 7) or mobilization group
(n¼ 8) (230–300 g). According to the Home Office license and
under aseptic conditions, a lateral approach was made to the
left femur. Using anatomical landmarks, and a custom
Figure 1. Experimental design and dosing schedule. Peripheral
blood MSC mobilisation study (a). Endogenous enhancement of
fracture healing study (b).
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precision jig-guide system, four bicortical threaded 1.4mm
stainless-steel fixator pins were consistently placed in the
craniomedial femur. Pins were exited through separate stab
incisions and the custom variable spacing fixator was
attached. A mid-diaphyseal femoral osteotomy, with no
periosteal stripping was made using a diamond tipped hand-
saw, while applying sterile saline coolant/lubricant. A preci-
sion spacer ensured a fixed distance between the cis cortex
and connecting blocks of 9mm. The fixator was then attached
and the osteotomy gap distracted to 1.5mm using a second
precision spacer. The biceps femoris was closed over the
osteotomy with a single horizontal mattress suture (1.5M
PDS II, Ethicon, UK), and then the skin was closed with
intradermal continuous suture (1.5M monocryl, Ethicon,
UK). Activity was unrestricted post surgery. Twenty-four
hours post-surgery, rats were given a single i.p. injection of
either VEGF (100mg/kg), or PBS once daily for four days. On
day five, they were given a single injection of AMD3100
(5mg/kg). All i.p. injections including AMD3100 and sham
PBS were administered at a volume of 0.5mls/100g body-
weight based on the day 0 pre-surgical weight (Fig. 1b). All
procedures were carried out at the Royal Veterinary College,
North Mymms, in accordance with the Animals Scientific
Procedures Act 1986, and aligned to the ARRIVE guidelines.
Those taking part in any surgical procedure held UK Home
Office licences. The dosages of VEGF and AMD3100 were
taken from Pitchford et al.11 and the timing of mobilisation
relative to surgery was based on prior work.16,17
After five weeks, the left femur including the fixator, were
retrieved from the sacrificed rats. Femurs were fixed and
scanned with a Bruker Skyscan 1172 micro-tomograph
machine (Bruker, Belgium), at 60KV, 167uA with a 0.5mm
aluminum filter. A rotation step of 0.5˚, without frame
averaging, and an image pixel size of 4.89mm. MicroCT scans
were reconstructed using NRecon (Bruker, Belgium). Analy-
sis was performed using CTAn (Bruker, Belgium). The
central 60% of the osteotomy gap was assessed (0.9mm¼ 180
slices at 5mm thick). Radiographic scouts were assessed for
bone union, using orthogonal projections isolated from the
microCT image acquisition series. Radiographs were evalu-
ated by three independent assessors in a randomized and
blinded manner and graded according to the RUST scoring.18
After microCT analysis, the bones were decalcified in
ethylenediaminetetraacetic acid (EDTA, Sigma–Aldrich), se-
quentially dehydrated in alcohol solutions, de-fatted and
embedded into wax with the fixator pins orthogonal to the
facing surface of the block. Fixator blocks and pins were
removed once the wax had set and a sledge microtome
(ThermoFisher Scientific, UK) was used to make 5mm thick
slices. The alignment of the blocks within the microtome was
altered as necessary to ensure a central sagittal slice through
the femur, assessed using the fixator pin tract holes. Slides
were prepared and stained with Haematoxylin and Eosin
(Sigma–Aldrich). Histomorphometric analyses were per-
formed at 2 magnification, quantified with a 1.5mm scaled
width line-intercept grid, with 120 intersections; grid squares
were 160mm in both directions. Intersections were then
scored as bone, cartilage, fibrous tissue, vascular or void.
Statistical Analysis
Due to the relatively small group sizes (n< 9), non-paramet-
ric tests were performed to compare groups including Mann–
Whitney U (MWU). Assessment of data spread was made
with a Levene’s test for equality of variance. Significance
was set a p< 0.05 and tests were analyzed with SPSS version
24 (IBM, Chicago). Data are expressed as meanSD unless
otherwise specified.
RESULTS
Comparison of BMMSCs to PBMSCs
BMMSCs formed fibroblastic colonies (CFUs) with
spindle shaped cells. P3 cells were able to differentia-
tion down osteogenic and adipogenic lines, with posi-
tive staining with Alizarin red and Oil red O,
respectively. BMMSCs had mean expression levels of
the following markers: CD45 5.7 5.0%, CD34
0.20.1%, CD29 98.4 4.1%, and CD90 98.91.0%.
No CFUs were isolated from the non-mobilized
control blood. The mobilized group formed CFU-Fs in
six out of the eight individual cultures. Initially, round
mononuclear cells were present with some immature
elongating cells. Over time, the cells began to take on
a similar morphology to those obtained by bone
marrow isolation; spindle or fibroblastic-shaped cells,
with a centrifugal arrangement of cells to form a
colony. Notably, however, they took longer to form
clear CFUs, typically around 14–18 days, when com-
pared with bone marrow isolated cells (5–7 days). The
mean CFU-F/ml for the mobilized group was signifi-
cantly higher at 2.91.8 CFU-F/ml (p¼ 0.029) than
the controls. These cells were passaged up to P3
(Fig. 2a shows bone marrow derived and 2b shows
blood mobilised MSCs).
Flow cytometry of P3 cells showed cells were CD34
negative, however, CD45 which is typically negative in
MSCs, was positive on some cells with both CD45
positive and CD45 negative cells present, varying from
Figure 2. Light microscopy image (10 magnifi-
cation) of third passage bone marrow derived
MSCs at day seven (a), compared third passage
day seven peripheral blood MSCs mobilized with
VEGF and AMD3100 (b). Bone marrow MSCs
were obtained from the femoral shaft of rats of a
similar age and isolated by plastic adherence.
Peripheral blood MSCs were obtained by cardiac
puncture 60min after a single dose of AMD3100,
preceded by a 4 day course of VEGF, once daily,
every 24h. The cells were isolated by plastic
adherence after lysing the red blood cells.
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9% to 60% positive within any population. MSC
markers CD90 and CD29 were relatively highly
expressed at 78% and 64%, respectively (See Table 1
for details).
In differentiation assays, mobilized P3 PBMSCs
formed a monolayer within seven days. During supple-
mentation with osteogenic media, the cell morphology
became less spindaloid and more cuboidal and multi-
ple small granules became apparent. Staining for
Alizarin red after 21 days demonstrated red stained
calcium deposits in all samples, consistent with osteo-
blast activity (n¼ 5) (see Fig. 3), however despite
adipogenic supplementation there was no evidence of
adipogenic differentiation, with no positive Oil Red O
staining evident in 4/5 and one showing a very small
amount. This was in contrast to the cells isolated
directly from the bone marrow, which demonstrated
mineralisation and lipid production when differenti-
ated down the respective lineages.
Influence of Mobilization on Fracture Healing
RUST scoring gave a mean of 7.71 2.7 for the control
group and 9.631.3 for the VEGF-AMD group (Fig. 4
shows a low scoring [a] and high scoring [b] example).
On microCT analysis, mobilized group (n¼ 8), showed
a higher mean bone volume than controls
(5.221.7mm3 vs. 4.33.1mm3), as well as increased
trabecular thickness (0.048 0.007mm vs.
0.042 0.003mm). The overall data spread was signifi-
cantly reduced in the VEGF-AMD3100 group when
looking at tissue volume (TV mm3, p¼0.036) and
trabecular number (p¼ 0.048) (Table 2).
Histomorphometric analysis revealed proportion-
ally greater levels of bone in the osteotomy of the
mobilized group; 55.17.8% bone, 40.99.8% carti-
lage, 0.30.8% fibrous, and 3.9 3.9% vascular
tissue (Fig. 5). The combined bone and cartilage
percentage was 963.7. This compared with control
osteotomy tissue composition of 39.123.9% bone,
43.1 24.6% cartilage, 15.337.4% fibrous and
2.4 2.0% vascular tissue; and the combined bone
and cartilage within the gap was 82.3 36.4%.
Levene’s test for equality of variances showed a
significant decrease in the variability of healing in
the mobilized group for bone (p¼0.032) and fibrous
tissue (p¼ 0.026).
DISCUSSION
This study has demonstrated a significant increase in
peripheral blood circulating PBMSCs post VEGF and
AMD3100 administration. Notably, they were morpho-
logically similar to BMMSCs, but were osteoblastic
lineage limited, and had lower levels of MSC markers
(CD90, and CD29) and higher levels of CD45, likely
indicating a heterogeneous population of adherent
fibroblastic expandable cells. Critically, the mobiliza-
tion of this population with VEGF and AMD3100 was
associated with an improvement in fracture healing.
Mobilized fractures had increased bone volume and
thicker struts of woven bone on micro CT analysis,
near doubling of union rates, with a significant reduc-
tion in data variation for the treated group on bone
volume from microCT data, and a smaller standard
deviation with the RUST radiographic score, with
improved means. This suggests mobilization may
preferentially have influence on the poorest healing
individuals, which may be clinically beneficial. Histol-
ogy corroborated the findings on microCT with an
increase in bone volume, vascularization and reduced
fibrous tissue within the osteotomy.
Under the in vitro protocol, no PBMSCs were
isolated from the non-mobilized blood samples. Others
have had more success,19 however, they used younger
animals. The isolation of cells was performed in ex-
breeders, which are adult through to geriatric, and age
related changes in stem cell differentiation, prolifera-
tion and metabolism20 are reported. Older rats have
fewer CFUs, fewer MSCs in the bone marrow,21
possibly explaining the reduced yields in non-mobi-
lized controls and mobilized groups compared with
Pitchford et al.,11 who used young mice. Humans also
show reduced CFUs with ageing6 and a recent study
also showed an age relationship with CXCR4 depen-
dent migration22 and hence the effect of antagonism of
the CXCR4-SDF1 axis may also reduce with age. Most
of the studies looking at peripheral blood circulating
stem cells and mobilization in animal models have
used young immature animals,11,17,19,23 and therefore
there may be merit in evaluating the role of age in
Table 1. Flow Cytometry Analysis of Cell Surface Marker Expression of VEGF AMD3100 Mobilized PBMSCs
CD34 CD34þ CD45þ CD45þ
Rat CD45þ CD34þ CD29þ CD90þ CD45 CD45 CD34 CD34þ
1 60.9 3.0 76.2 77.8 37.0 2.6 59.3 1.0
2 35.4 1.8 60.7 83.9 61.3 2.2 36.1 0.4
3 8.6 1.8 55.2 70.7 87.0 2.3 10.6 0.2
Mean 35.0 26.2 2.2 0.7 64.0 10.9 77.5 6.6 61.8 25.0 2.4 0.2 35.3 24.2 0.5 0.4
The three right hand columns show the co-expression of CD markers. In cells from all the rats there is low expression of CD34 but in 2
of the animals investigated there is a relatively high co-expression of CD45, which is usually not found on MSCs. There is high
expression of CD29 and CD90, which are known MSC markers.
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mobilization potential. Although the rats were not
ovariectomized, assessing mobilization in ex-breeders
is more relevant, as the likely target population for
translation will be fractures in older patients and in
those with osteoporosis where fracture healing is more
likely to be impaired than in young individuals.
It is assumed that the mobilized cells are of bone
marrow origin, however, with systemic administration
of the mobilizing agents, they may be from other
niches, particularly when considering the conservation
of SDF1-CXCR4 axis goes beyond the bone marrow
niche.10,24,25 It is certainly suggested that the bone
marrow makes a contribution to the mobilized periph-
erally circulating cells, as demonstrated by isolating
the femoral artery and vein11 to evaluate mobilization
Figure 3. Light microscopy images (10 magnification) of third
passage cells from peripheral blood MSCs in rats treated with
VEGF and AMD3100. The cells were cultured with osteogenic
supplements for 21 days and stained with Alizarin red demon-
strating mineral formation. Each row represents a culture from a
different rat.
Figure 4. MicroCT scout radiographs, showing an example of
the 1.5mm gap control group (a) and the VEGF AMD3100
treated group (b) taken after 5 weeks This shows a non-union at
5 weeks in the control animal with union and bone formation in
the gap in the treated animal.
Table 2. MicroCT Quantitative Morphometry Indices of
Bone Formation Within the 60% of the Osteotomy Gap
Where TV (mm3)¼Tissue Volume, BV (mm3)¼Bone
Volume, TV/BV (%)¼Percentage Bone Volume, TS
(mm2)¼Tissue Surface, BS (mm2)¼Bone Surface, Tb.Th
(mm)¼Trabecular Thickness, Tb.Sp (mm)¼Trabecular
Separation, Tb.N (1/mm)¼Trabecular Number
MicroCT Parameter 1.5mm Control VEGF-AMD
TV (mm3) 9.23 6.14 10.03 3.22
BV (mm3) 4.31 3.08 5.22 1.71
TV/BV (%) 53.79 20.82 52.52 5.85
TS (mm2) 62.83 45.55 63.56 19.88
BS (mm2) 326.15 220.05 355.52 130.15
Tb.Th (mm) 0.04 0.01 0.05 0.01
Tb.Sp (mm) 0.07 0.03 0.08 0.02
Tb.N (1/mm) 14.09 9.32 10.99 1.08
Total Porosity (%) 46.21 20.82 47.48 5.85
MicroCT analysis of the mobilized group showed a higher mean
bone volume than controls as well as increased trabecular
thickness. The overall data spread was analyzed using a Levene’s
test for equality of variance and found to be significantly reduced
in VEGF-AMD3100 group for tissue volume (TVmm3, p¼ 0.036)
and trabecular number (p¼ 0.048), suggesting less variation in
degree of healing between individuals.
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from an isolated body compartment. The authors
suggest that the cells are therefore bone marrow in
origin, however an isolated femoral component actu-
ally only informs of all possible niches within the hind
limb, and not exclusively the bone marrow compart-
ment. It remains possible that these cells were mobi-
lized from sources other than the bone marrow, such
as the periosteum, muscle or perivascular niches.26
Interestingly the mobilized cells did not have adipo-
genic potential, but had effective osteoblastic differen-
tiation, which may be important for bone tissue
engineering. The traditional view is that a single MSC
would be capable of differentiation into osteoblasts,
chondrocytes or adipocytes. Even classical bone mar-
row stem cell work has shown different clonal popula-
tions frequently do not have full tri-differentiation,
while interestingly, the osteogenic lineage is always
present.27 Other studies have suggested a hierarchy of
sequential lineage loss with the potential for osteo-
genic differentiation remaining.28
They showed that only 1/3 clones were capable of
tri-differentiation, and the majority were osteo or
chondro orientated. Due to the paucity of cells and the
long duration of culture required with PBMSCs, there
were insufficient cells for pellet culture and chondro-
genic differentiation, and therefore it remains unclear
if the PBMSCs could also be differentiated into
chondrocytes. The PBMSCs mobilized had similar cell
surface marker expression as the BMMSCs, although
CD29 and CD90 were not as highly expressed. Notably
there appeared to be the presence of two CD45
populations; CD45 and CD45þ groups, both without
CD34 expression. CD45 is a key leukocyte marker and
MSCs are universally considered to be CD45-29,30;
however, CD45 has been demonstrated on cultured
bone marrow MSCs from patients with haematological
malignancies. These cells could differentiate and were
morphologically similar to CD45- MSCs, and hence
under certain circumstances the CD45 rule may be
broken.31 It is impossible to tell if these cells were
simply contaminants or did represent a CD45þ MSC
population. Other studies in rabbits32 and a compre-
hensive comparison of rat bone marrow to blood MSCs
showed no difference in CD marker expression, mor-
phology and tri-lineage potential, although growth and
differentiation potential are reduced in peripheral
blood isolated MSCs.33
Although VEGF with AMD3100 statistically in-
creased the yields of PBMSCs, they were still rela-
tively low. Conceptually, a single CFU is produced
Figure 5. MicroCT 3D reconstructions of mid femoral regions, with a mid-sagittal reveal showing the associated mid sagittal
histology section, stained with hematoxylin and eosin, centered on the osteotomy at 2.5 magnification, and then enhanced region at
5 magnification. An example from a non-treated control animal is shown in the upper images and a VEGF/AMD3100 treated animal
in the lower images. The microCT in control groups show limited union with a large gap, which has not been filled-in with bone. In the
control animal there is also evidence of cortical bone resorption although a periosteal callus has formed. The microCT from the VEGF-
AMD3100 group shows almost complete bone union in the periosteal callus, and incomplete union in the endosteal callus, with the
osteotomy filled with mostly mineralized tissue. Histology shows that the tissue in the gap of the control animal is composed of
cartilage while cartilage is present in the gap in the treated animal there are regions where bone bridges between the fracture ends
have formed. The white line encircles a small region of remaining cartilage within the osteotomy in the treated animal.
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from a single stem/progenitor.5 In this model system,
the average yield of three stem/progenitor cells per ml
of blood combined with a maximum 6–10ml available
made evaluation challenging. To that end, in vitro
identification with expansion was necessary, and
allowed a wider platform of evaluation, although cell
expansion was also slow. This methodology was simi-
lar to Pitchford’s work in mice,11 however, they
showed in young mice greater stem cell mobilization of
15 MSCs/ml blood. This finding, may be an artefact of
in vitro culture and the processing performed to
remove red blood cells prior to culture, or relate to
species or age differences in the donors. The problems
of isolating stem cells from the peripheral circulation
is not new however, and other groups have used fibrin
microbeads that bind matrix-dependent cells to con-
centrate the proportion of MSCs within MNCs to
improve subsequent plating density and yields.34 A
further consideration is the single time point of
sampling, which essentially provides only a “snap-
shot” of the circulating pool.
Evidently, the mobilization of a peripheral blood
MSC like osteoblastic progenitor was beneficial in a
compromised fracture healing environment. Previous
work using a similar fixator system showed complete
union at five weeks with a 0.5mm osteotomy and an
atrophic non-union with a 3mm osteotomy.35 A
1.5mm osteotomy was chosen as a half-way measure
with the expectation of compromised healing as a good
test base for the effect of mobilization on fracture
healing. This study was the first study to evaluate the
potential effects of stem-progenitor mobilization on
fracture healing in rats. Critically, it evaluated the
potential to recue a compromised healing environ-
ment, rather than simply augmenting an uncompli-
cated healing situation.
Mobilization using VEGF with AMD3100, improved
fracture healing, with an increased RUST score. The
trabecular thickness and the space between trabecular
(trabecular separation) evaluation output provides
commentary on the nature of the woven bone formed
within the osteotomy in this instance. The mobilized
group had an increased the trabecular separation,
implying of the bone formed was more porous, but
increase trabecular thickness suggested the individual
struts were thicker. Perhaps this represents a more
advanced or more rapidly developed stage of endochon-
dral ossification. In any case, VEGF with AMD3100
increased the bone formation over the controls. Others
have seen improvements in fracture healing using
AMD3100 alone,17 or combined with IGF1.16 These
models were in young mice and showed improved
healing, in a non-compromised situation. There is
therefore cross-species merit in this strategy, and the
ideal mobilization protocol remains unclear, particular
in a compromised healing environment which may be
a more appropriate test system considering the likely
translation. Notably, on microCT and histomorphomet-
ric analysis, the variation in healing was significantly
reduced with VEGF-AMD3100 treatment, perhaps
indicating it improved the poorer healing individuals
more than the better healing ones, and thus decreased
the variability of healing seen in the controls.
Clearly the nature of the disturbance to the SDF1-
CXCR4 axis is important. It is likely that a short
duration blockade will mobilize more stem and progen-
itor cells and hence increase the total pool available to
the fracture site. However, the homing to the fracture
site also relies upon the very interaction being antago-
nized. The short half-life of AMD3100,14 likely pro-
vides a “pulse” in the early inflammatory phase of
fracture healing has more mobilizing effect at the bone
marrow or other niches, rather than significantly
impairing the recruitment of cells to the fracture site
over days to weeks. Longer term blockade throughout
the period of fracture healing will significantly reduce
callus cartilage, callus size and bone formation, with
reduced expression of genes associated with endochon-
dral ossification.10 Continued AMD3100 administra-
tion also reduces new bone formation in distraction
osteogenesis models,36 and therefore the timing of the
administration of VEGF and AMD3100 relative to the
stage of fracture healing is likely to be crucial and
warrants further investigation.
A difference between the CFU mobilization analysis
and the subsequent evaluation in fracture healing in
this study is presence and influence of the osteotomy.
It is well know that fractures release increased levels
of growth factors.37 Clinically, VEGF has been shown
to be increased in human patients with long bone
fractures within the first couple of weeks, lasting up to
six months post trauma.38 Conceivably the administra-
tion of VEGF which is thought to pre-prime the bone
marrow to preferentially release MSCs when
ADM3100 is given,11 could have had direct humoral
influence on the fracture healing itself, irrespective of
stem cell mobilization. Histomorphometric assessment
of vascularisation in the mobilized group showed
higher levels of blood vessels, and VEGF is a known
potent angiogenesis promoter with a clear role in
endochondral and intramembranous bone forma-
tion.39,40 Exogenous VEGF administration will inevita-
bly have both direct and indirect effects on bone
formation. VEGF can act indirectly through its recep-
tors on endothelial cells, influencing the development
of a new vascular network, allowing bone orientated
stem and progenitors to migrate into the fracture
callus and differentiate into osteoblasts.41
An important aspect of any evaluation of fracture
healing is associated with the functional results. There
have been a number of articles that assessed the
strength of repair and the degree of bone formation.
The majority of these show good correlation, however,
this was not performed in this proof of concept study
due to the increased numbers of rats that would have
been required to achieve sufficient statistical power.
Now that we have established efficacy, future dose
regime evaluations would include this aspect.
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In order to progress this study further it may be
necessary to optimise the administration of both
VEGF and AMD3100. In this instance we chose to
administer the protocol immediately after fracture,
during the early inflammatory phase of fracture heal-
ing, when stem cells will be recruited, and is consis-
tent with other studies.16,17 This is sensible based on
the translational potential of this treatment as it
would have to be given after a fracture occurred, but
could be instigated early on as a prophylactic in “at
risk” fracture patients such as fragility fractures.
Nonetheless, the optimal timing of the administration
of VEGF and AMD3100 relative to the stage of
fracture healing could impact on its influence on
fracture healing and warrants further investigation.
Different dosing or timings, such as repeated injec-
tions of AMD3100, may increase the circulating pool of
MSCs, however, for these cells to be effective they
have to home to the site of fracture through the SDF1
CXCR4 interaction. Fortunately the half-life of
AMD3100 is short allowing the cells to re-establish
their homing capacity, and only studies that gave
AMD3100 throughout the entire fracture healing
process showed impaired healing.10
Future mechanistic work could include spiking the
circulation with labeled stem cells at the same time
that AMD3100 is administered, and then investigating
the efficiency of these cells to migrate to the fracture
suite over time. However, there is an issue of deter-
mining cell migration characteristics from cultured
cells as cell surface protein expression critical for
migration and homing are influenced by in vitro cell
culture. Whether or not cultured labelled cells would
reflect the in vivo kinetics of uncultured cell migration
is unclear. Only bone marrow ablation with recapitula-
tion with labelled marrow, or parabiotic studies could
adequately answer this question and they are highly
problematic to perform due to significant animal
welfare implications.
There are other methods that may be used to
enhance mobilisation of stem cells. For example Meng
et al. transfected MSCs to express Aquaporin, a
regulator of endothelial cell migration, and showed the
cells had enhanced migration in a transwell assay.42
SOX 11 transfected stem cells transcriptionally acti-
vate Runx2 and CXCR4 expression, and when admin-
istered in a rat femoral fracture model they showed a
larger number of MSCs migrated to the fracture site
and improved bone fracture healing.43 While these
studies show that migration of cells can be manipu-
lated and can improve bone healing in fracture models,
the advantage of our approach where the CXCR4/
SDF1 axis is disrupted means that cells are not
manipulated in vitro, and the approach is entirely
endogenous.
Further work to determine the influence of age on
mobilization, the role of other cells populations mobi-
lized and optimization of both the in vitro assessment
and the dose/timing of therapy, and combinations of
other growth factors with AMD3100 should be pur-
sued. In conclusion, VEGF combined with AMD3100
can mobilize a population of MSC-like osteoblastic
lineage determined cells into the peripheral circulation
and this leads to increases in bone formation in a
delay union osteotomy model. Notably, this approach
shows promise in a challenging fracture-healing envi-
ronment, which differentiates this work from prior
studies augmenting normal healing, and for the first
time, a MSC mobilising protocol of VEGF-AMD3100
has been evaluated. Clinically there could be signifi-
cant benefit to fragility and other at risk fracture to
provide a “biological boost” to the fracture healing
process in at risk patients, through this non-invasive
endogenous strategy.
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